PO.CH02.02 · 化学

使用HCR™ Gold和MoxiePlex在FFPE肿瘤中对临床相关的蛋白和RNA靶标进行9通道空间共检测

9-channel spatial co-detection of clinically relevant protein and RNA targets in FFPE tumors with HCR™ Gold and MoxiePlex

编号 7673 展板 27 时间 4/22 09:00–12:00 区域 Section 38 主讲 Wudy Yang
分会场 Multi-Omics, Systems Biology, and Biological Mass Spectrometry
该海报暂无可下载的资料 AACR 官方页面

作者与单位 Authors & Affiliations

Wudy Yang1, Randy Chen1, Harry Choi1, Aneesh Acharya1, Minakshi Singh2, Quyen Vu3

1Molecular Instruments, Inc., Los Angeles, CA,2Hamamatsu Photonics Europe GmbH, Herrsching am Ammersee, Germany,3Hamamatsu Corporation, Bridgewater, NJ

摘要 Abstract

中文摘要
背景:FFPE肿瘤中蛋白和RNA的高重数空间分析对于表征肿瘤-免疫相互作用日益重要,但现有方法往往将探索局限于预定义的抗体面板、剧烈的剥脱/洗脱步骤,以及有损样本和靶标完整性、使检测开发和验证繁重的迭代循环。由HiFi编码器赋能的HCR™ Gold IF支持使用未修饰的、用户自备的一抗进行无酶荧光检测,并与HCR™ Gold RNA-FISH运行在同一扩增平台上。结合Hamamatsu MoxiePlex多光谱组织成像平台——该平台无需循环染色即可对7-9重面板进行全玻片单轮成像——这一工作流程为FFPE标本中灵活的7-9重蛋白和RNA共检测提供了一条实用途径。 方法:FFPE人肿瘤切片使用HCR™ Gold IF进行染色,采用经编码的、临床验证的一抗以及HCR™ HiFi探针。在MoxiePlex上测试了两种并行的多重配置:1. 7重面板:DAPI、425、488、546、594、700、750;2. 9重面板:DAPI、425、488、514、546、594、633、700、750。面板纳入了针对癌症相关蛋白(如pan-CK、Ki-67、PD-L1、CD8、CD68)和代表肿瘤及免疫生物学的RNA靶标(如EPCAM、CXCL9、CD274)的抗体。对每种荧光染料-靶标组合,均生成单染参考玻片以确定曝光设置、验证滤光片性能,并量化光谱渗漏以实现光谱解混。多重玻片在单次采集轮次中成像,数据从信号强度、通道串扰、预期生物学定位以及与单染参考的一致性方面进行评估。光谱解混在采集后作为成像过程的一部分对全玻片图像自动进行。 结果:HCR™ Gold IF和HCR™ Gold RNA-FISH产生了明亮、稳健的信号,并保持了组织结构。在全玻片多重成像中,蛋白和RNA靶标定位于预期的肿瘤和基质区域,突显了肿瘤微环境中的免疫浸润,其表达与单染参考模式高度吻合。MoxiePlex平台提供了一致的全玻片成像性能,采集设置可重复,适合常规的7-9重扫描。 结论:HCR™ Gold IF和HCR™ Gold RNA-FISH可在MoxiePlex上以单轮工作流程结合使用,实现对FFPE组织中临床相关蛋白和RNA靶标高达9重的成像。该方法避免了剥脱或光漂白,保持了与经验证抗体和标准滤光片组的兼容性,并为转化和临床研究中灵活的7-9重空间检测提供了一条实用途径。
查看英文原文 English abstract
Background: High-plex spatial profiling of protein & RNA in FFPE tumors is increasingly important for characterizing tumor-immune interactions, but existing methods often limit exploration to predefined antibody panels, harsh stripping/eluting steps, and iterative cycles that compromise sample and target integrity and make assay development and validation burdensome. HCR™ Gold IF, enabled by the HiFi Encoder, supports enzyme-free fluorescent detection using unmodified, user-supplied primary antibodies and operates on the same amplification platform as HCR™ Gold RNA-FISH. Combined with the Hamamatsu MoxiePlex multispectral tissue imaging platform, which enables whole-slide single-round imaging of 7-9-plex panels without the need for cyclic-staining, this workflow offers a practical route to flexible, 7-9-plex protein and RNA co-detection in FFPE specimens. Methods: FFPE human tumor sections were stained with HCR™ Gold IF using encoded, clinically validated primary antibodies alongside HCR™ HiFi Probes. Two parallel multiplex configurations were tested on the MoxiePlex:1. 7-plex panel: DAPI, 425, 488, 546, 594, 700, 7502. 9-plex panel: DAPI, 425, 488, 514, 546, 594, 633, 700, 750Panels incorporated antibodies specific to cancer-relevant proteins (e.g., pan-CK, Ki-67, PD-L1, CD8, CD68) & RNA targets representing tumor and immune biology (e.g., EPCAM, CXCL9, CD274). For each fluorophore-target combination, single-stain reference slides were generated to establish exposure settings, verify filter performance, and quantify spectral bleed-through to enable spectral unmxing. Multiplex slides were imaged in a single acquisition round, and data were evaluated for signal intensity, channel crosstalk, expected biological localization, and concordance with single-stain references. Spectral unmixing was carried out automatically for the whole- slide image, following acquisition, as part of the imaging process. Results: HCR™ Gold IF & HCR™ Gold RNA-FISH produced bright, robust signals with preserved tissue architecture. In whole- slide multiplex imaging, protein and RNA targets localized to expected tumor and stroma regions highlighting immune infliltration in the tumor microenvironment, the expression of which. closely matched single-stain reference patterns. The MoxiePlex platform delivered consistent, whole-slide imaging performance with reproducible acquisition settings appropriate for routine 7-9-plex scanning. Conclusions: HCR™ Gold IF & HCR™ Gold RNA-FISH can be combined in a single-round workflow on the MoxiePlex to achieve up to 9-plex imaging of clinically relevant protein and RNA targets in FFPE tissue. This approach avoids stripping or photobleaching, maintains compatibility with validated antibodies and standard filter sets, and provides a practical path for flexible, 7-9-plex spatial assays in translational and clinical research.
利益披露 Disclosure
W. Yang, None.. R. Chen, None.. H. Choi, None.. A. Acharya, None.. M. Singh, None.. Q. Vu, None.

← 返回 AACR 2026 检索